Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0VIMVV)
| ADC Name |
ALX2004
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
ALX2004
Click to Show/Hide
|
|||||
| Organization |
ALX Oncology (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-EGFR antibody
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
TOP1 inhibitor
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Oesophageal cancer | ||||
| Colorectal cancer | ||||
| Lung cancer | ||||
| Head and neck cancer |